Myeloperoxidase

Where the papers sit

12 papers from the last 6 months study myeloperoxidase directly · updated from PubMed 1 Nov 2026

• MPO Therapeutics and Detection

  Mitiperstat pharmacokinetics and computational inhibitor discovery pursue MPO suppression, while Fe3O4 nanozymes pair peroxidase-like catalysis with doxorubicin delivery in cancer models. Other work addresses CAR engineering of granulocyte-monocyte progenitors, synovial-fluid MPO after regenerative injections, and electrochemical aptamer sensing. These efforts share MPO as a target or readout but not a disease, intervention, or endpoint. No single translational direction is established across the cluster.

  6 papers · 50%

• MPO-Associated Inflammatory Disease

  ANCA-associated glomerulonephritis and diabetic kidney disease link MPO-related neutrophil inflammation to renal injury. Pediatric IgA deposition and decade-long ANCA testing emphasize diagnostic strategy and disease heterogeneity. In diabetic kidney disease, MPO and NE mRNA rise by stage and track independently with albuminuria. MPO and G-CSF also recur as markers of intracranial atherosclerosis progression, extending the question from renal diagnosis to vascular risk.

  4 papers · 33.3%

• MPO Activity Detection Assays

  Serum-compatible MPO activity testing is moving toward CRISPR/Cas12a readouts that work in fluorescence and lateral-flow formats. Aptamer regulation, RCA, DNA-nanowire scaffolds and trans-cleavage cascades are used to improve sensitivity and manage serum interference. The recurring goal is lower detection limits without sacrificing practical sample compatibility. Whether these platforms outperform conventional assays in clinical samples remains open.

  2 papers · 16.7%